Lexaria Bioscience (LEXX) Projected to Post Quarterly Earnings on Monday

Lexaria Bioscience (NASDAQ:LEXX) is anticipated to post its results before the market opens on Monday, April 13th. Analysts expect Lexaria Bioscience to post earnings of ($0.0950) per share and revenue of $0.05 million for the quarter.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Lexaria Bioscience had a negative return on equity of 226.58% and a negative net margin of 1,685.84%.The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Lexaria Bioscience to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexaria Bioscience Stock Performance

NASDAQ LEXX opened at $1.04 on Monday. The stock has a market capitalization of $25.89 million, a PE ratio of -1.86 and a beta of 0.48. The stock has a 50-day simple moving average of $0.73 and a 200 day simple moving average of $0.86. Lexaria Bioscience has a twelve month low of $0.46 and a twelve month high of $1.69.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LEXX. Weiss Ratings reissued a “sell (e+)” rating on shares of Lexaria Bioscience in a report on Monday, December 29th. HC Wainwright lowered their price target on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating on the stock in a research note on Friday, December 26th. Finally, Wall Street Zen cut Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $1.50.

Hedge Funds Weigh In On Lexaria Bioscience

An institutional investor recently bought a new position in Lexaria Bioscience stock. Virtu Financial LLC bought a new stake in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.13% of Lexaria Bioscience as of its most recent filing with the SEC. 13.06% of the stock is currently owned by institutional investors and hedge funds.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.